Nanomolar EP4 Receptor Potency and Expression of Eicosanoid-related Enzymes in Normal Appearing Colonic Mucosa from Patients with Colorectal Neoplasia

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2022 May 13

PMID 35549670

Authors

Ulrike Ries Feddersen

Sebastian Kjaergaard Hendel

Mark Alexander Berner-Hansen

Thomas Andrew Jepps

Mark Berner-Hansen

Niels Bindslev

Affiliations

Soon will be listed here.

Abstract

Background: Aberrations in cyclooxygenase and lipoxygenase (LOX) pathways in non-neoplastic, normal appearing mucosa from patients with colorectal neoplasia (CRN), could hypothetically qualify as predisposing CRN-markers.

Methods: To test this hypothesis, biopsies were obtained during colonoscopy from macroscopically normal colonic mucosa from patients with and without CRN. Prostaglandin E2 (PGE) receptors, EP1-4, were examined in Ussing-chambers by exposing biopsies to selective EP receptor agonists, antagonists and PGE. Furthermore, mRNA expression of EP receptors, prostanoid synthases and LOX enzymes were evaluated with qPCR.

Results: Data suggest that PGE binds to both high and low affinity EP receptors. In particular, PGE demonstrated EP4 receptor potency in the low nanomolar range. Similar results were detected using EP2 and EP4 agonists. In CRN patients, mRNA-levels were higher for EP1 and EP2 receptors and for enzymes prostaglandin-I synthase, 5-LOX, 12-LOX and 15-LOX.

Conclusions: In conclusion, normal appearing colonic mucosa from CRN patients demonstrates deviating expression in eicosanoid pathways, which might indicate a likely predisposition for early CRN development and furthermore that PGE potently activates high affinity EP4 receptor subtypes, supporting relevance of testing EP4 antagonists in colorectal neoplasia management.

Citing Articles

In vitro models and ex vivo systems used in inflammatory bowel disease.

Joshi A, Soni A, Acharya S In Vitro Model. 2023; 1(3):213-227.

PMID: 37519330 PMC: 9036838. DOI: 10.1007/s44164-022-00017-w.

Correction: Nanomolar EP4 receptor potency and expression of eicosanoid-related enzymes in normal appearing colonic mucosa from patients with colorectal neoplasia.

Feddersen U, Hendel S, Berner-Hansen M, Jepps T, Berner-Hansen M, Bindslev N BMC Gastroenterol. 2022; 22(1):298.

PMID: 35715746 PMC: 9206375. DOI: 10.1186/s12876-022-02339-1.

References

Larsen R, Mertz-Nielsen A, Hansen M, Poulsen S, Bindslev N . Novel modified Ussing chamber for the study of absorption and secretion in human endoscopic biopsies. Acta Physiol Scand. 2001; 173(2):213-22. DOI: 10.1046/j.1365-201X.2001.00865.x. View

Eberhart C, Coffey R, Radhika A, Giardiello F, Ferrenbach S, DuBois R . Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994; 107(4):1183-8. DOI: 10.1016/0016-5085(94)90246-1. View

Facista A, Nguyen H, Lewis C, Prasad A, Ramsey L, Zaitlin B . Deficient expression of DNA repair enzymes in early progression to sporadic colon cancer. Genome Integr. 2012; 3(1):3. PMC: 3351028. DOI: 10.1186/2041-9414-3-3. View

Karpisheh V, Joshi N, Zekiy A, Beyzai B, Hojjat-Farsangi M, Namdar A . EP4 receptor as a novel promising therapeutic target in colon cancer. Pathol Res Pract. 2020; 216(12):153247. DOI: 10.1016/j.prp.2020.153247. View

Lochhead P, Chan A, Nishihara R, Fuchs C, Beck A, Giovannucci E . Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol. 2014; 28(1):14-29. PMC: 4265316. DOI: 10.1038/modpathol.2014.81. View

Drew D, Cao Y, Chan A . Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer. 2016; 16(3):173-86. PMC: 6741347. DOI: 10.1038/nrc.2016.4. View

Sugimoto Y, Narumiya S . Prostaglandin E receptors. J Biol Chem. 2007; 282(16):11613-7. DOI: 10.1074/jbc.R600038200. View

Petersen C, Mahmood B, Badsted C, Dahlby T, Rasmussen H, Hansen M . Possible predisposition for colorectal carcinogenesis due to altered gene expressions in normal appearing mucosa from patients with colorectal neoplasia. BMC Cancer. 2019; 19(1):643. PMC: 6599319. DOI: 10.1186/s12885-019-5833-8. View

Hawthorn L, Lan L, Mojica W . Evidence for field effect cancerization in colorectal cancer. Genomics. 2013; 103(2-3):211-21. DOI: 10.1016/j.ygeno.2013.11.003. View

10.

Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S . Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med. 2001; 7(9):1048-51. DOI: 10.1038/nm0901-1048. View

11.

Rigas B, Goldman I, Levine L . Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993; 122(5):518-23. View

12.

Pidgeon G, Lysaght J, Krishnamoorthy S, Reynolds J, OByrne K, Nie D . Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev. 2007; 26(3-4):503-24. DOI: 10.1007/s10555-007-9098-3. View

13.

Thun M, Jacobs E, Patrono C . The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012; 9(5):259-67. DOI: 10.1038/nrclinonc.2011.199. View

14.

Billot X, Chateauneuf A, Chauret N, Denis D, Greig G, Mathieu M . Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. Bioorg Med Chem Lett. 2003; 13(6):1129-32. DOI: 10.1016/s0960-894x(03)00042-8. View

15.

Melstrom L, Bentrem D, Salabat M, Kennedy T, Ding X, Strouch M . Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res. 2008; 14(20):6525-30. DOI: 10.1158/1078-0432.CCR-07-4631. View

16.

Loeb L, Bielas J, Beckman R . Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 2008; 68(10):3551-7. DOI: 10.1158/0008-5472.CAN-07-5835. View

17.

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A . Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034. PMC: 126239. DOI: 10.1186/gb-2002-3-7-research0034. View

18.

Sanz-Pamplona R, Berenguer A, Cordero D, Mollevi D, Crous-Bou M, Sole X . Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer. Mol Cancer. 2014; 13:46. PMC: 4023701. DOI: 10.1186/1476-4598-13-46. View

19.

Rebello D, Rebello E, Custodio M, Xu X, Gandhi S, Roy H . Field carcinogenesis for risk stratification of colorectal cancer. Adv Cancer Res. 2021; 151:305-344. DOI: 10.1016/bs.acr.2021.03.004. View

20.

Wang D, DuBois R . Prostaglandins and cancer. Gut. 2005; 55(1):115-22. PMC: 1856377. DOI: 10.1136/gut.2004.047100. View